SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Omnicell, Inc. (OMCL) News

Follow Omnicell, Inc. (OMCL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 23 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol OMCL Asset equity Sector Markets 90 days 19 Last 32.465 Updated Oct 29, 2026, 01:03 PM UTC Open live news feed Open OMCL chart & news
M Omnicell Reports Q3 2026 Revenue of $307.9 Million, Adjusted EPS of $0.58 Q3 revenue and adjusted EPS exceeded FactSet estimates of $304.4 million and $0.42, respectively. Omnicell forecast Q4 revenue of $295.0 million to $301.0 million and adjusted EPS of $0.41 to $0.49; FY2026 revenue guidan EQUITY | Oct 29, 2026, 01:03 PM UTC M Omnicell Q3 Profit Rises on Connected-Device Demand EQUITY | Oct 29, 2026, 10:47 AM UTC M Omnicell Issues Q4 Adjusted EPS Outlook EARNINGS | Oct 29, 2026, 10:41 AM UTC M Omnicell forecasts FY revenue of $1.225B-$1.231B EARNINGS | Oct 29, 2026, 10:41 AM UTC M Omnicell Issues Q4 Adjusted Revenue Outlook EQUITY | Oct 29, 2026, 10:41 AM UTC M Omnicell More Than Doubles Third-Quarter 2026 Net Profit EARNINGS | Oct 29, 2026, 10:40 AM UTC M Omnicell Reports Third-Quarter Revenue of $307.9M EQUITY | Oct 29, 2026, 10:39 AM UTC L Omnicell Reports 3Q Net Income of $11M EARNINGS | Oct 29, 2026, 10:39 AM UTC M Omnicell Reports Q3 Net Income of $11 Million EARNINGS | Oct 29, 2026, 10:32 AM UTC M Omnicell Reports Q3 Revenue of USD 308 Million EQUITY | Oct 29, 2026, 10:32 AM UTC L Omnicell reports Q3 adjusted EBITDA of $45 million EARNINGS | Oct 29, 2026, 10:32 AM UTC M Omnicell Announces Third-Quarter 2026 Financial Results EQUITY | Oct 29, 2026, 10:31 AM UTC M Omnicell Reports Third-Quarter 2026 Results, Updates Guidance Omnicell reported third-quarter 2026 financial results and updated its full-year 2026 guidance. EQUITY | Oct 29, 2026, 10:31 AM UTC L OMCL: Transformation centers on Titan XT and OmniSphere, with disciplined growth and innovation focus Management is driving a multi-year transformation with the Titan XT and OmniSphere platforms, focusing on innovation, customer experience, and flexible upgrade paths. Financial discipline is prioritized, with targeted in EQUITY | Sep 09, 2026, 06:22 PM UTC L OMCL: Titan XT and OmniSphere drive innovation, margin focus, and market share gains in a robust refresh cycle Management is driving a multi-year transformation with the Titan XT and OmniSphere platforms, focusing on innovation, customer experience, and flexible financing to capture market share. Margin expansion and disciplined EQUITY | Sep 09, 2026, 05:51 PM UTC L TraceLink and Omnicell integrate DSCSA compliance into hospital pharmacies TraceLink and Omnicell say their DSCSA compliance solution will bring serialized product verification and traceability into medication receiving workflows, aimed at enabling more efficient hospital pharmacy operations wi EQUITY | Sep 03, 2026, 02:01 PM UTC L OMCL - TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations OMCL - TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations EQUITY | Sep 03, 2026, 02:00 PM UTC L Omnicell to present at Wells Fargo 21st Healthcare Conference Omnicell will present at the Wells Fargo 21st Annual Healthcare Conference. EQUITY | Aug 31, 2026, 08:01 PM UTC L OMCL Reiterate Overweight after two day NDR meetings @ KEYB OMCL Reiterate Overweight after two day NDR meetings @ KEYB EQUITY | Aug 24, 2026, 11:51 AM UTC L OMCL Q2 saw solid results, but reduced the low end of its FY26 product bookings guide @ KEYB OMCL Q2 saw solid results, but reduced the low end of its FY26 product bookings guide @ KEYB EQUITY | Jul 31, 2026, 11:01 AM UTC L Omnicell Raises FY2026 Adj EPS Guidance from $1.80-$2.00 to $2.15-$2.30 vs $1.94 Est; Narrows FY2026 Sales Guidance from $1.215B-$1.255B to Omnicell (NASDAQ: OMCL ) raises FY2026 Adj EPS guidance from $1.80-$2.00 to $2.15-$2.30 vs $1.94 analyst estimate. Narrows FY2026 sales outlook from $1.215 billion-$1.255 billion to $1.225 billion-$1.245 billion vs $1.24 EARNINGS | Jul 30, 2026, 10:40 AM UTC L OMCL Omnicell RESULTS: Q2, Q2 REV $312M, Q2 ADJ EBITDA $67M, Q2 Net Income $24M, Q2 ADJ Net Income $44M, Omnicell Earnings Notes:, Outlook Q OMCL Omnicell RESULTS: Q2, Q2 REV $312M, Q2 ADJ EBITDA $67M, Q2 Net Income $24M, Q2 ADJ Net Income $44M, Omnicell Earnings Notes:, Outlook Q3 ADJ EPS $0.35-0.43, Guides Q3 2026 REV $301M-$307M EARNINGS | Jul 30, 2026, 10:32 AM UTC L Omnicell Appoints COO Nnamdi Njoku As President, Effective July 1 Omnicell, Inc. (NASDAQ: OMCL ) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Nnamdi Njoku has been appointed Presiden GEOPOLITICS | Jul 01, 2026, 12:16 PM UTC